drugset
drugset / Trial / NCT00122486

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122486 ↗

Phase 2 Completed 1200 enrolled FHI 360
RandomizedParallel-groupDouble-blindPrevention

Summary

This Phase 2 study involving tenofovir disoproxil fumarate (TDF) will assess the extended safety of TDF 300 mg per day among young women who are not HIV-infected.

Timeline

Start
2004-07
Primary completion
—
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 300 mg —

Indications

HIV infectious disease